Skip to main content

IDSA: MVA-BN Vaccine Against Mpox Tolerated, Effective for Teens

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 18, 2024.

via HealthDay

THURSDAY, Oct. 17, 2024 -- The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine, licensed in the United States to prevent smallpox and mpox, is well tolerated and seems effective in adolescents, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 16 to 19 in Los Angeles.

Catherine Mary Healy, M.D., from Baylor College of Medicine in Houston, and colleagues examined the safety and immunogenicity of two doses of MVA-BN vaccine administered subcutaneously 28 days apart in adolescents aged 12 to 17 years compared to adults (aged 18 to 50 years) in a phase 2, open-label, multisite clinical trial. A total of 315 adolescents were compared to 211 adults.

The researchers found that both groups had similar solicited systemic and local events and unsolicited adverse events. Adolescents had dizziness more often (nine events in eight patients versus none in adults), which was similar to rates reported after other adolescent vaccines. MVA-BN was well tolerated overall. The day 43 antibody responses elicited by MVA-BN in adolescents were noninferior to the response in adults (geometric mean titer ratio for adolescents to adults, 1.60).

"These findings mark an important milestone for people living in areas with mpox," Healy said in a statement. "This mpox vaccine is an increasingly important solution to protect vulnerable adolescents and manage current and future outbreaks."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab

TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV)...

2020 to 2024 Saw Drop in Flu Vaccine Uptake Among U.S. Adults

FRIDAY, July 18, 2025 -- There was an overall decrease in influenza vaccine uptake among U.S. adults from 2020 to 2024, according to a study published online July 16 in PLOS...

No Risks Seen With Early Childhood Exposure to Aluminum-Adsorbed Vaccines

TUESDAY, July 15, 2025 -- Early childhood exposure to aluminum-adsorbed vaccines is not associated with an increased risk for autoimmune, atopic or allergic, or neurodevelopmental...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.